Azelastine HCL: A review of the old and new formulations

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 427-437

  Horbal, Jonathan M ^a   Bernstein, Jonathan A ^b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Azelastine HC1; Non allergic vasomotor rhinitis; SAR; Seasonal allergic rhinitis; VMR

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEPRO; AZELASTINE; CETIRIZINE; CHLORPHENIRAMINE; DRUG METABOLITE; ERYTHROMYCIN; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LEUKOTRIENE B4; LEUKOTRIENE C4; MOMETASONE FUROATE; NITRIC OXIDE; NORAZELASTINE; NOSE SPRAY; PLACEBO; SORBITOL; SUCRALOSE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BITTER TASTE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; HAY FEVER; HISTAMINE RELEASE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NASAL DISCOMFORT; NONHUMAN; NOSE ULCER; PATIENT COMPLIANCE; PERENNIAL RHINITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SNEEZING; SOMNOLENCE; SYMPTOM; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; VASOMOTOR RHINITIS;

EID: 77952689541     PISSN: None     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/cmt.s3865     Document Type: Review

References (44)

1. Bernstein JA. Characteristics of Nonallergic Vasomotor Rhinitis. World Allergy Journal. 2009;2:102-5.
2. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc. 2001;22:185-9.
3. Lieberman P, Kaliner MA, Wheeler WJ. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin. 2005;21:611-8.
4. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 2000;85:338-47 quiz 47-8.
5. Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007;23:2441-52.
6. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1-84.
7. Bousquet J, Bodez T, Gehano P, Klossek JM, Liard F, Neukirch F, et al. Implementation of guidelines for allergic rhinitis in specialist practices. A randomized pragmatic controlled trial. Int Arch Allergy Immunol. 2009;150:75-82.
8. Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, et al. ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006;117:1054-62.
9. Berger WE. Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis. Expert Opin Drug Metab Toxicol. 2009;5:91-102.
10. Azelastine (Astepro) nasal spray for allergic rhinitis. Med Lett Drugs Ther. 2009;51:29-30.
11. Brandt D, Bernstein JA. Questionnaire evaluation and risk factor identification for nonallergic vasomotor rhinitis. Ann Allergy Asthma Immunol. 2006;96:526-32.
12. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
13. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-334.
14. Kaliner M, Farrar, JR. Consensus Review and Definition of Nonallergic Rhinitis With a Focus on Vasomotor Rhinitis, Proposed to be known henceforth as Nonallergic Rhinopathy: Introduction to Part 2. World Allergy Journal. 2009;2:155.
15. Devyani LC, JP. Vasomotor rhinitis update. Curr Opin Otolaryngol Head Neck Surg. 2004;12:243-7.
16. Bernstein JA, Rezvani M. Mixed Rhinitis: A new subclass of chronic rhinitis? Current Rev of Rhinitis. 2006:69-78.
17. Pharmaceuticals M. US full prescribing information. www.astelin.com/Astelin.Public/AstelinPI.pdf 2006.
18. Astepro 0.15% package insert. Medpointe Pharmaceuticals.
19. Pharmalex SA. Azelastine (Allergodil): identification of the pharmacological receptors involved in non H1-dependent anti-inflammatory actions. Medpointe Pharmaceuticals; Data on file. Protocol Scientifique NPS. 1979;1000:6
20. Casale TB. The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol. 1989;83:771-6.
21. Chand N, Pillar J, Nolan K, Diamantis W, Sofia RD. Inhibition of allergic and nonallergic leukotriene C4 formation and histamine secretion by azelastine: implication for its mechanism of action. Int Arch Allergy Appl Immunol. 1989;90:67-70.
22. Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Grogen J, Mela GS, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol. 1996;98:1088-96.
23. Ito H, Nakamura Y, Takagi S, Sakai K. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung. 1998;48:1143-7.
24. Shinoda M, Watanabe N, Suko T, Mogi G, Takeyama M. Effects of antiallergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Am J Rhinol. 1997;11:237-41.
25. Nieber K, Baumgarten C, Rathsack R, Furkert J, Laake E, Muller S, et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy. 1993;23:69-71.
26. Hamasaki Y, Shafigeh M, Yamamoto S, Sato R, Zaitu M, Muro E, et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol. 1996;76:469-75.
27. Shin MH, Baroody F, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. The effect of azelastine on the early allergic response. Clin Exp Allergy. 1992;22:289-95.
28. Hide I, Toriu N, Nuibe T, Inoue A, Hide M, Yamamoto S, et al. Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. J Immunol. 1997;159:2932-40.
29. Matsuo S, Takayama S. Influence of the anti-allergic agent, azelastine, on tumor necrosis factor-alpha (TNF-alpha) secretion from cultured mouse mast cells. In Vivo. 1998;12:481-4.
30. Yoneda K, Yamamoto T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol. 1997;73:145-53.
31. Astepro. Meda Pharmaceuticals package insert.
32. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol. 1997;99:S742-9.
33. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;104:364-9.
34. Meltzer EO, Weiler JM, Dockhorn RJ, Widlitz MD, Freitag JJ. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy. 1994;72:354-9.
35. Weiler JM, Meltzer EO, Benson PM, Weiler K, Widlitz MD, Freitag J. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol. 1994;94:972-80.
36. Patel P, D'Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21:499-503.
37. Ratner PH, Findlay SR, Hampel F Jr, van Bavel J, Widlitz MD, Freitag JJ. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1994;94:818-25.
38. Berger W, Hampel F Jr, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97:375-81.
39. Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther. 2005;27:543-53.
40. Banov CH, Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001;86:28-35.
41. Lumry W, Prenner B, Corren J, Wheeler W. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann Allergy Asthma Immunol. 2007;99:267-72.
42. LaForce C, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol. 1996;76:181-8.
43. Bernstein JA, Ferguson B, Portnoy J, Wheeler W, Sacks H. Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. Journal of Rhinopathy. 2009; In press
44. Howard J. Disposition of azelastine HCl in subjects with hepatic dysfunction and with renal impariment. Medpointe Pharmaceuticals; Data on file.